Izvorni znanstveni članak

SERUM LEVELS OF INTERLEUKIN-6 AND TUMOR NECROSIS FACTOR-ALPHA IN EXACERBATION AND REMISSION PHASE OF SCHIZOPHRENIA

Bojana Dunjic-Kostic ; Clinic for Psychiatry, Clinical Centre of Serbia, Belgrade, Serbia
Miroslava Jasovic-Gasic ; School of Medicine, University of Belgrade, Belgrade, Serbia, Academy of Medical Science, Serbian Medical Society, Belgrade, Serbia
Maja Ivkovic ; School of Medicine, University of Belgrade, Belgrade, Serbia, Clinic for Psychiatry, Clinical Centre of Serbia, Belgrade, Serbia
Nevena V. Radonjic ; School of Medicine, University of Belgrade, Belgrade, Serbia, Institute of Clinical and Medical Biochemistry, Belgrade, Serbia
Maja Pantovic ; Clinic for Psychiatry, Clinical Centre of Serbia, Belgrade, Serbia
Aleksandar Damjanovic ; School of Medicine, University of Belgrade, Belgrade, Serbia, Clinic for Psychiatry, Clinical Centre of Serbia, Belgrade, Serbia
Sanja Totic Poznanovic ; School of Medicine, University of Belgrade, Belgrade, Serbia, Clinic for Psychiatry, Clinical Centre of Serbia, Belgrade, Serbia
Aleksandar Jovanovic ; School of Medicine, University of Belgrade, Belgrade, Serbia, Clinic for Psychiatry, Clinical Centre of Serbia, Belgrade, Serbia
Tatjana Nikolic ; School of Medicine, University of Belgrade, Belgrade, Serbia, Institute of Clinical and Medical Biochemistry, Belgrade, Serbia
Natasa D. Petronijevic ; School of Medicine, University of Belgrade, Belgrade, Serbia, Institute of Clinical and Medical Biochemistry, Belgrade, Serbia

Sažetak

Background: The variations in proinflamatory cytokine levels have been associated with schizophrenia (SCH), duration of illness,
psychopathology and treatment. The aim of the study was to investigate serum levels of interleukin-6 (IL-6) and tumor necrosis factoralpha
(TNF-α) in schizophrenic patients during exacerbation and remission, and its association with course of illness and therapy.
Subjects and methods: We measured serum levels of IL-6 and TNF-α in 43 schizophrenic patients in exacerbation and remission
and compared them to 29 healthy controls, matched by sex, age, body mass index (BMI) and smoking habits. The severity of
psychopathology was assessed using the Positive and Negative Syndrome Scale (PANSS).
Results: There was no difference in levels of IL-6 and TNF-α in exacerbation compared to remission in schizophrenic patients.
IL-6 was higher and TNF-α was lower in schizophrenic patients in both exacerbation and remission in comparison with healthy
controls. TNF-α in exacerbation was in negative correlation with IL-6 in remission. No statistical significance was found between
levels of cytokines and sex, age, BMI, smoking habits, antipsychotic medication, duration of treatment and duration of illness. IL-6
levels were in positive correlation with the age of onset and the duration of untreated psychosis. In schizophrenic patients on
adjunctive treatment with mood stabilizers, TNF-α levels increased in remission.
Conclusion: Our results suggest that the connection between schizophrenia, cytokines and medication is multifaceted, and not
necessarily linear. Adjunct mood stabilizers not only ameliorate psychopathology, but might convey immunomodulatory effects as
well. Further longitudinal studies could elucidate potential beneficial effect of combined therapy in treatment of SCH.

Ključne riječi

schizophrenia - tumor necrosis factor-alpha - interleukin-6 – antipsychotics - mood stabilizers

Hrčak ID:

159845

URI

https://hrcak.srce.hr/159845

Datum izdavanja:

4.3.2013.

Posjeta: 680 *